NCT00219180View on ClinicalTrials.gov

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

PHASE3CompletedINTERVENTIONAL
Enrollment

1,797

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Hypertension
Interventions
DRUG

aliskiren

Trial Locations (2)

07936

Novartis Pharmaceuticals, East Hanover

Unknown

Investigative Centers

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00219180 - Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure | Biotech Hunter | Biotech Hunter